TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Dynavax ( (DVAX) ) has provided an update.
On October 15, 2025, Dynavax Technologies Corporation’s Board of Directors approved changes in its management structure. David F. Novack will transition from his roles as President and Chief Operating Officer to Senior Vice President and Chief Operating Officer, effective January 1, 2026. Additionally, Robert Janssen, M.D. will be removed from his roles as Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs, with his employment concluding by March 2, 2026, as the company searches for a successor.
The most recent analyst rating on (DVAX) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Dynavax stock, see the DVAX Stock Forecast page.
Spark’s Take on DVAX Stock
According to Spark, TipRanks’ AI Analyst, DVAX is a Neutral.
Dynavax’s overall stock score is driven by strong earnings call results, showcasing record revenue and strategic growth initiatives. However, financial performance and valuation concerns, including negative profitability metrics and a lack of dividend yield, weigh down the score. Technical analysis indicates a neutral to slightly negative trend, further impacting the overall assessment.
To see Spark’s full report on DVAX stock, click here.
More about Dynavax
Dynavax Technologies Corporation operates in the biotechnology industry, focusing on developing and commercializing novel vaccines and immunotherapy products.
Average Trading Volume: 1,613,650
Technical Sentiment Signal: Sell
Current Market Cap: $1.16B
See more insights into DVAX stock on TipRanks’ Stock Analysis page.